IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial - Wikidata - awgldk - TriplyDB

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

http://www.wikidata.org/entity/Q28364218

about

Immunotherapy for advanced renal cell cancer Immunotherapy for advanced renal cell cancer Sunitinib in the treatment of metastatic renal cell carcinoma Immunotherapy for metastatic renal cell carcinoma.Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (D Immunotherapy of metastatic renal cell cancer.Evolving immunotherapeutic strategies in bladder and renal cancer Therapeutic approaches in metastatic renal cell carcinoma.Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).Allogeneic stem cell transplantation for patients with metastatic renal cell carcinoma.Immunotherapy options in metastatic renal cell cancer: where we are and where we are going.IPM chemotherapy in cytokine refractory renal cell cancer.Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma.Establishing the role of cytokine therapy in advanced renal cell carcinoma.Adjuvant therapy in renal cell carcinoma-past, present, and future.Immunotherapy for renal cell cancer in the era of targeted therapy.Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline.Metastatic renal carcinoma comprehensive prognostic system Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs.Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review.Role of cytokine therapy for renal cell carcinoma in the era of targeted agents.Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.Different responses to two types of 5-fluorouracil prodrugs in combination with interferon-alpha in pulmonary metastases of renal cell carcinoma: a case report.Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma.Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity.Treatment of renal cell carcinoma: Current status and future directions.Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.Metastatic renal cell carcinoma presenting in the external auditory canal.An update on current management of advanced renal cell cancer, biomarkers, and future directions Is there a role for adjuvant therapy after surgery in “high risk for recurrence” kidney cancer? An update on current concepts

P2860

Q24187300-A0B5DC85-6DB1-4EAF-A8F9-292D8CCB31C5 Q24246777-4A7F2707-EBB9-4744-8016-BE59A2364986 Q28072057-23603C93-F9F4-4329-B244-AC0D89162F2F Q30234458-DB10551A-C16E-423A-B59B-3BE3EC4DCD8D Q33716744-2158E71A-D22B-4687-B0ED-C8CCDF95D939 Q34555854-CE50547A-BC28-44D6-B936-BA8FD2771037 Q34849167-C5E7F41D-DB1F-44B4-ADBD-5F9E43B139B9 Q35519671-B96569C5-231F-45AA-B5CF-DF28BE827BD3 Q36118589-56124FC5-5182-4187-A753-E9AFAE77804C Q36612231-13196D1B-A7F9-42E0-B554-889C1FC3BCC1 Q36636648-A2C66F06-712D-4BD1-9F63-C6F0B8E9ADE9 Q36636651-16DB7909-A596-46E7-8848-0C1190A5E4AB Q36648893-B3553293-4ADD-4BCA-9844-2F41EC5BFDFC Q36696255-9A711DE8-5A81-4A36-9C6C-8EA1B943DEDE Q36710382-E78D8A3F-2F90-43A0-96D6-506481D00B7F Q37086157-B7FF8ACD-4E0A-436B-9C51-600B7CBCA8DD Q37153437-A4B1D4F3-F008-413C-B2B8-41AA1D147BC6 Q37183451-39E9C0F6-DFE0-4835-B4A4-17A91AA6723F Q37187448-38A4EAB6-DCFD-4066-AB9A-0436C8BA79D2 Q37354998-4F521D10-4D38-4ABA-A403-68D98EE34615 Q37418672-B84CA3D8-35AE-4F87-850B-471D683E1582 Q38233353-C88ABBD4-9967-4C37-A96A-9FD6259BE38C Q41895084-D0197827-27D4-4DB7-8D13-3DF8F3D09D57 Q41898172-8F1F6696-087C-4290-A67B-42A9E03AC1C5 Q42549684-2CE04C97-E2A3-43B4-BE1F-03ACEE870573 Q44124135-8221B6C7-4E5C-4B99-8244-AC690851A993 Q44954461-5A754831-1292-4E6F-8647-42E39318BC64 Q47726014-43C47977-D26D-408F-9C39-45F5229F6729 Q51112501-0D463FF4-D139-48E2-BB9A-69940338CB0A Q53559604-A8C90800-B812-41DE-A0BE-07825D89F5E4 Q56897121-574829EB-E76A-4E7B-84B9-03ED35C1A945 Q59126184-61646702-495D-49DF-954B-A96A8736504B

P2860

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

http://www.wikidata.org/entity/Q28364218

description

2001 nî lūn-bûn

@nan

2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

IL-2 in combination with IFN- ...... lled randomized clinical trial

@ast

IL-2 in combination with IFN- ...... lled randomized clinical trial

@en

IL-2 in combination with IFN- ...... lled randomized clinical trial

@nl

type

label

IL-2 in combination with IFN- ...... lled randomized clinical trial

@ast

IL-2 in combination with IFN- ...... lled randomized clinical trial

@en

IL-2 in combination with IFN- ...... lled randomized clinical trial

@nl

prefLabel

IL-2 in combination with IFN- ...... lled randomized clinical trial

@ast

IL-2 in combination with IFN- ...... lled randomized clinical trial

@en

IL-2 in combination with IFN- ...... lled randomized clinical trial

@nl

P1433

Q28364218-C08ED263-A505-41C3-B873-042C3812A1DF

P1476

Q28364218-A10F847B-337F-4653-8A32-A1ED120A2B21

P2093

Q28364218-04B76B0F-961C-40E5-9253-52213686429D

Q28364218-2B65C37F-0370-4DAE-B7C2-F340DE2FAFDD

Q28364218-30E67A45-B57C-4641-A5F0-C6F799885B36

Q28364218-41A221F7-B74D-487B-981B-C26E1BB12129

Q28364218-4F289DB0-E2B1-4507-BA54-42B301F5E9B9

Q28364218-68DD5432-5B8B-4D83-9196-90FDF4EBA9E1

Q28364218-90B254F9-E6AE-407A-99FA-A984348FC596

Q28364218-B1C86F6B-6131-4BCB-82F3-BE7D3EAC5106

Q28364218-C3496A99-5654-41B8-BB67-B7BD63E93D0C

Q28364218-D5D4178F-97C4-4B69-BF13-B409921511CF

P2860

Q28364218-118B2DE1-B692-4096-A762-EAED561BECEB

Q28364218-13F3E29E-69D5-4E60-B306-EFA3070A47D6

Q28364218-186B37AE-CD3F-459B-80CB-EDB8DD2579DC

Q28364218-1D6F2E9F-9CAC-45E2-A5CB-7CEBAD98D90E

Q28364218-408BAB41-B421-4D57-85DC-DAA1B3A80167

Q28364218-5FF92E35-6F76-4111-AD78-6E62A8C625FF

Q28364218-61754833-7EC7-4EA1-8567-4E834D0CCBAC

Q28364218-6ABB47B1-5C12-4FB7-BE98-3A24D003E4CD

Q28364218-75D793DA-D765-41D4-A801-A6691D4A7DB4

Q28364218-8E0477D6-0DFA-4329-91FE-B1A86EBB38AB

P2888

Q28364218-3246BA10-594E-4285-9B3A-77C009852C66

P304

Q28364218-41ACB525-603B-467A-8955-5B3BA68738AB

P31

Q28364218-F92039DA-5D80-470C-B994-E94FFDAA08B2

P356

Q28364218-A7536C62-158C-4FE7-BBA9-18EB622A0659

P407

Q28364218-2B33DB81-2F44-421D-B3B0-04071CE71E3B

P433

Q28364218-43632549-7713-4CA6-ABD6-6E9E0418BC2E

P478

Q28364218-9C0D15EC-93EA-4859-9D74-900FEEB785E8

P577

Q28364218-A417998E-B96E-47AB-9DF0-8E5E6A97923C

P5875

Q28364218-EABFBD11-9D8B-4C5F-853D-9F19B2015228

P6179

Q28364218-EBAA792C-B4C6-40A2-8E10-FA7F7AAF5B92

P698

Q28364218-7BE6F15D-08C8-4A2E-AD98-6B6A9DA22816

P921

Q28364218-34B59305-528A-40F2-9059-15DCA2C5B327

P932

Q28364218-70644EA1-4E2D-4204-9914-B93D9A6A468C

P356

P1433

British Journal of Cancer

P1476

IL-2 in combination with IFN- ...... lled randomized clinical trial

@en

P2093

B Metzner

http://www.w3.org/2001/XMLSchema#string

D Ukena

http://www.w3.org/2001/XMLSchema#string

H J Illiger

http://www.w3.org/2001/XMLSchema#string

H Kirchner

http://www.w3.org/2001/XMLSchema#string

H Schott

http://www.w3.org/2001/XMLSchema#string

J Atzpodien

http://www.w3.org/2001/XMLSchema#string

M Gramatzki

http://www.w3.org/2001/XMLSchema#string

M Reitz

http://www.w3.org/2001/XMLSchema#string

P J Funke

http://www.w3.org/2001/XMLSchema#string

S Jürgenson

http://www.w3.org/2001/XMLSchema#string

P2860

Cytokines and cytotoxic agents in renal cell carcinoma: a review.

Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.

Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.

The current use of interferons, interleukin-2 and tumor necrosis factor in renal cell cancer.

A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation.

Therapeutic options in renal-cell carcinoma.

Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.

Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma.

Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.

P2888

P304

1130-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1054/BJOC.2001.2076

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P577

2001-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11644031

http://www.w3.org/2001/XMLSchema#string

P6179

1037245726

http://www.w3.org/2001/XMLSchema#string

P698

11710825

http://www.w3.org/2001/XMLSchema#string

P921

P932

2375150

http://www.w3.org/2001/XMLSchema#string